Your browser doesn't support javascript.
CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis.
Gunaratne, Shauna H; Tieu, Hong-Van; Wilkin, Timothy J; Taylor, Barbara S.
  • Gunaratne SH; Columbia University Irving Medical Center, New York, New York, USA.
  • Tieu HV; Columbia University Irving Medical Center and Weill Cornell Medicine, New York, New York, USA.
  • Wilkin TJ; Weill Cornell Medicine, New York, New York, USA.
  • Taylor BS; University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.
Top Antivir Med ; 30(3): 490-521, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-2101976
ABSTRACT
The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich source of new data and comprehensive reviews on antiviral therapy. For COVID-19, intramuscular sotrovimab was noninferior to intravenous sotrovimab, serostatus did not predict the efficacy of sotrovimab, and molnupiravir appeared safe and modestly effective in decreasing hospitalization rates. Trials from low- and middle-income countries provided data to support transitioning those on first-line therapy with or without virologic suppression and those virologically suppressed on second-line therapy to dolutegravir-based regimens. Additional data supported the use of lenacapavir as a long-acting antiretroviral drug. Data across the United States demonstrate the negative impact of the COVID-19 pandemic on the HIV care continuum, although enhanced outreach efforts and decentralization of antiretroviral therapy delivery were associated with improvements in care engagement outcomes. Researchers described potential mechanisms for the emergence of integrase strand transfer inhibitor resistance. Studies on proviral genotyping high-lighted the limitations of its use in predicting clinically significant resistance. Several studies looked at the epidemiology and treatment of hepatitis C and B and the status of current hepatitis C virus elimination efforts. Data presented on HIV, COVID-19, and maternal and pediatric health included 2-year virologic outcome data of very early antiretroviral therapy in potentially reducing the latent HIV reservoir in infants with HIV. Data presented on COVID-19 and HIV therapeutics in children included SARS-CoV-2-neutralizing monoclonal antibodies in children younger than 12 years of age, remdesivir in hospitalized infants and children, and long-acting therapies for HIV treatment in children.
Asunto(s)

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Tratamiento Farmacológico de COVID-19 / Hepatitis Viral Humana Tipo de estudio: Estudio observacional / Estudio pronóstico Límite: Niño / Humanos País/Región como asunto: America del Norte Idioma: Inglés Revista: Top Antivir Med Año: 2022 Tipo del documento: Artículo País de afiliación: Estados Unidos

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Tratamiento Farmacológico de COVID-19 / Hepatitis Viral Humana Tipo de estudio: Estudio observacional / Estudio pronóstico Límite: Niño / Humanos País/Región como asunto: America del Norte Idioma: Inglés Revista: Top Antivir Med Año: 2022 Tipo del documento: Artículo País de afiliación: Estados Unidos